SPRY Live signals | Maximize Profits with Getagraph.com

SELL 106464 min ago

@ $7.11

Issued: 14 Feb 2024 @ 09:30

Return: 17.44%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.32 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	511 249
Average Volume	694 576
Market Cap	805.79M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.110 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.65
ATR14	$0.0110 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Tanimoto Sarina	Buy	48 260	Common Stock
2024-04-23	Tanimoto Sarina	Buy	82 733	Common Stock
2024-04-23	Tanimoto Sarina	Sell	48 260	Stock Option (right to buy)
2024-04-23	Tanimoto Sarina	Sell	82 733	Stock Option (right to buy)
2024-04-23	Lowenthal Richard E	Buy	48 260	Common Stock

INSIDER POWER
52.08
Last 100 transactions
Buy: 17 636 525 \| Sell: 6 045 288

Volume Correlation

Long: -0.08 (neutral)

Short: -0.71 (moderate negative)

Signal:(29.271) Neutral

ARS Pharmaceuticals, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ARS Pharmaceuticals, Inc. Correlation - Currency/Commodity

0.76
( moderate )

0.74
( moderate )

0.00
( neutral )

0.60
( weak )

0.00
( neutral )

-0.51
( weak negative )

ARS Pharmaceuticals, Inc. Financials

Annual	2023
Revenue:	$30 000.00
Gross Profit:	$-43 000.00 (-143.33 %)
EPS:	$-0.570

FY	2023
Revenue:	$30 000.00
Gross Profit:	$-43 000.00 (-143.33 %)
EPS:	$-0.570

FY	2022
Revenue:	$1.32M
Gross Profit:	$-16.00M (-1 216.11 %)
EPS:	$-0.850

FY	2021
Revenue:	$5.51M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.216

Financial Reports:

No articles found.

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.